GH Research (GHRS) Operating Income (2020 - 2025)
GH Research's (GHRS) quarterly Operating Income came in at -$16.7 million in Q4 2025, down 29.15% year-on-year from -$23.6 million in Q4 2024, and down 0.92% quarter-over-quarter from -$16.6 million in Q3 2025.
GH Research (GHRS) Operating Income (2020 - 2025) Analysis & Trends
GH Research's Operating Income history runs 6 years deep, the most recent figure standing at -$16.7 million for Q4 2025.
- On a quarterly basis, Operating Income fell 29.15% year-over-year to -$16.7 million in Q4 2025; TTM through Dec 2025 was -$60.7 million, a 20.68% decrease from a year earlier, with the FY2025 full-year figure at -$60.7 million, down 20.68% from the prior year.
- Operating Income slipped to -$16.7 million in Q4 2025 per GHRS's latest filing, from -$16.6 million in the prior quarter.
- Across five years, Operating Income topped out at -$1.1 million in Q1 2021 and bottomed at -$16.7 million in Q4 2025.
- The 5-year median for Operating Income is -$10.2 million (2023), against an average of -$9.9 million.
- Across the five-year window, Operating Income slumped 7676.67% in 2021 and decreased 10.44% in 2025, its largest moves.
- Year by year, Operating Income stood at -$6.6 million in 2021, then sank by 38.53% to -$9.2 million in 2022, then slipped by 21.66% to -$11.2 million in 2023, then declined by 16.0% to -$12.9 million in 2024, then dropped by 29.15% to -$16.7 million in 2025.
- Per Business Quant, the three latest GHRS Operating Income figures stand at -$16.7 million (Q4 2025), -$16.6 million (Q3 2025), and -$14.7 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | GH Research | 1.69 Bn | 1.69 Bn | - | -16.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16.72 Mn |
| Sep 30, 2025 | -16.57 Mn |
| Jun 30, 2025 | -14.70 Mn |
| Mar 31, 2025 | -12.73 Mn |
| Dec 31, 2024 | -12.94 Mn |
| Sep 30, 2024 | -12.62 Mn |
| Jun 30, 2024 | -13.22 Mn |
| Mar 31, 2024 | -11.53 Mn |
| Dec 31, 2023 | -11.16 Mn |
| Sep 30, 2023 | -9.72 Mn |
| Jun 30, 2023 | -9.93 Mn |
| Mar 31, 2023 | -10.42 Mn |
| Dec 31, 2022 | -9.17 Mn |
| Sep 30, 2022 | -6.63 Mn |
| Jun 30, 2022 | -6.75 Mn |
| Mar 31, 2022 | -8.01 Mn |
| Dec 31, 2021 | -6.62 Mn |
| Sep 30, 2021 | -4.67 Mn |
| Jun 30, 2021 | -2.67 Mn |
| Mar 31, 2021 | -1.14 Mn |